FDA approves Darzalex Faspro as quad regimen for all newly diagnosed MM
cancerletter.com/drugs-and-targets/2…
FDA approves Darzalex Faspro as quad regimen for all newly diagnosed MM - The Cancer Letter
FDA has approved Darzalez Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients, regardless of transplant eligibility. To access this […]
